- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05739656
Evaluation of Visual Acuity of the Envista One-piece Acrylic Toric IOL MX60ET
A PROSPECTIVE, MULTICENTER, POST-MARKET OBSERVATIONAL STUDY TO EVALUATE ROTATIONAL STABILITY AND FUNCTIONAL VISUAL ACUITY OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TORIC IOL MX60ET FOLLOWING CATARACT SURGERY PROTOCOL.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75243
- Jeffrey Whitman, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects must be able to read, understand, and provide written informed consent on the Institutional Review Board (IRB)-approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations.
- Subjects must be able and willing to comply with all treatment and follow-up/study procedures.
- Subjects must be 18 years of age or older on the date the ICF is signed.
- Subjects must have best-corrected distance visual acuity (BCDVA) equal to or worse than 20/40 in the study eye, with or without glare source, due to a clinically significant cataract (either cortical, nuclear, subcapsular, or a combination) that is considered amenable to treatment with standard phacoemulsification cataract extraction.
- Subjects must require a spherical equivalent lens power from 17.0 D to 24.0 D in the study eye.
- Subjects must have a BCDVA projected to be better than 20/30 after toric IOL implantation in the study eye (as determined by the medical judgment of the Investigator or measured by potential VA testing if necessary).
- Subjects must have a preoperative corneal astigmatism between 0.77 D and 4.53 D in the study eye.
- Subject must have a dilated preoperative pupil size greater than or equal to 5.0 mm in the study eye.
Contact lens wearers need to demonstrate a stable refraction (within
±0.50 D) in the study eye, as determined by manifest refraction spherical equivalent (MRSE) on two consecutive examination dates. Stability of the refraction is determined under the following conditions:
- Lenses are not worn for at least 2 weeks (rigid or toric contact lenses) or 3 days (soft contact lenses) prior to the first refraction used to establish stability and through the day of surgery.
- The two refractions are performed at least 7 days apart.
Exclusion Criteria:
This study will exclude subjects who meet none of the following exclusion criteria:
- Subjects with any anterior segment pathology in the study eye likely to increase the risk of complications from phacoemulsification cataract surgery (eg, chronic uveitis, iritis, iridocyclitis, rubeosis iridis, clinically significant corneal dystrophy, clinically significant Fuchs' dystrophy, clinically significant anterior membrane dystrophy, etc).
- Subjects with associated ocular conditions which could affect the stability of the IOL (eg, traumatic zonulolysis, zonular dialysis, evident zonular weakness or dehiscence, etc) in the study eye.
- Subjects with clinically significant irregular corneal astigmatism in the study eye, as determined by the medical judgment of the Investigator.
- Subjects with clinically significant corneal pathology potentially affecting topography of either eye.
- Subjects with any ocular condition (eg, amblyopia) that could prevent the possibility of a visual outcome better than 20/30 in the study eye.
- Subjects with an anterior chamber depth < 2.0 mm as measured by the IOL master/LENSTAR in the study eye.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Effectiveness Endpoint
Time Frame: The duration of the study, including the time to recruit all subjects, will be up to 12 months. Eligible subjects who are enrolled in the study will be seen for up to 6 months after implantation.
|
The proportion of subjects with absolute lens axis rotation from surgical placement of less than or equal to 20 degrees. Tertiary/Supportive/Other effectiveness outcomes will include the following.
|
The duration of the study, including the time to recruit all subjects, will be up to 12 months. Eligible subjects who are enrolled in the study will be seen for up to 6 months after implantation.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 897 (Other Grant/Funding Number: M.S.I. Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Astigmatism
-
Ohio State UniversityCompletedAstigmatism BilateralUnited States
-
Coopervision, Inc.Completed
-
Cairo UniversityUnknown
-
Assiut UniversityCompleted
-
Ashford and St. Peter's Hospitals NHS TrustBausch & Lomb IncorporatedUnknown
-
Carl Zeiss Meditec, Inc.CompletedMixed AstigmatismUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Ziemer Ophthalmic Systems AGTigermed Consulting Co., LtdRecruitingMyopic AstigmatismChina
-
Bausch & Lomb IncorporatedCompleted
-
Staar Surgical CompanyActive, not recruiting
Clinical Trials on CATARACT SURGERY
-
Iladevi Cataract and IOL Research CenterCompletedCataract Surgery | Shallow Anterior Chamber | PhacoemulsificationIndia
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
University of OklahomaCompletedPrimary Open Angle Glaucoma | Cataract | Pigmentary GlaucomaUnited States
-
Glaukos CorporationCompletedOpen-Angle GlaucomaUnited States
-
Ziemer Ophthalmic Systems AGRecruiting
-
Technolas Perfect Vision GmbHCompleted
-
Sun Yat-sen UniversityCompleted
-
Guy's and St Thomas' NHS Foundation TrustCompletedCataract | Surgery
-
University Hospital, BordeauxCompleted